These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 20412588)

  • 1. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).
    Poynard T; Lebray P; Ingiliz P; Varaut A; Varsat B; Ngo Y; Norha P; Munteanu M; Drane F; Messous D; Bismut FI; Carrau JP; Massard J; Ratziu V; Giordanella JP
    BMC Gastroenterol; 2010 Apr; 10():40. PubMed ID: 20412588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease.
    Ratziu V; Massard J; Charlotte F; Messous D; Imbert-Bismut F; Bonyhay L; Tahiri M; Munteanu M; Thabut D; Cadranel JF; Le Bail B; de Ledinghen V; Poynard T; ;
    BMC Gastroenterol; 2006 Feb; 6():6. PubMed ID: 16503961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.
    Poynard T; Munteanu M; Deckmyn O; Ngo Y; Drane F; Messous D; Castille JM; Housset C; Ratziu V; Imbert-Bismut F
    BMC Gastroenterol; 2011 Apr; 11():39. PubMed ID: 21492460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.
    Poynard T; Munteanu M; Deckmyn O; Ngo Y; Drane F; Castille JM; Housset C; Ratziu V; Imbert-Bismut F
    J Hepatol; 2012 Sep; 57(3):541-8. PubMed ID: 22612998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers.
    Vermehren J; Vermehren A; Mueller A; Carlebach A; Lutz T; Gute P; Knecht G; Sarrazin C; Friedrich-Rust M; Forestier N; Poynard T; Zeuzem S; Herrmann E; Hofmann WP
    BMC Gastroenterol; 2012 Mar; 12():27. PubMed ID: 22453133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.
    de Lédinghen V; Vergniol J; Gonzalez C; Foucher J; Maury E; Chemineau L; Villars S; Gin H; Rigalleau V
    Dig Liver Dis; 2012 May; 44(5):413-8. PubMed ID: 22285146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B.
    Kim BK; Kim SU; Kim HS; Park JY; Ahn SH; Chon CY; Cho IR; Joh DH; Park YN; Han KH; Kim DY
    PLoS One; 2012; 7(4):e35825. PubMed ID: 22536445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C.
    Ngo Y; Munteanu M; Messous D; Charlotte F; Imbert-Bismut F; Thabut D; Lebray P; Thibault V; Benhamou Y; Moussalli J; Ratziu V; Poynard T
    Clin Chem; 2006 Oct; 52(10):1887-96. PubMed ID: 16931569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordance between liver biopsy and FibroTest in assessing liver fibrosis in chronic hepatitis B.
    Park MS; Kim BK; Cheong JY; Kim DJ; Park JY; Kim DY; Ahn SH; Han KH; Chon CY; Kim SU
    PLoS One; 2013; 8(2):e55759. PubMed ID: 23405210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study.
    Halfon P; Bourliere M; Deydier R; Botta-Fridlund D; Renou C; Tran A; Portal I; Allemand I; Bertrand JJ; Rosenthal-Allieri A; Rotily M; Sattonet C; Benderitter T; Saint Paul MC; Bonnot HP; Penaranda G; Degott C; Masseyeff MF; Ouzan D
    Am J Gastroenterol; 2006 Mar; 101(3):547-55. PubMed ID: 16542291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.
    Salkic NN; Jovanovic P; Hauser G; Brcic M
    Am J Gastroenterol; 2014 Jun; 109(6):796-809. PubMed ID: 24535095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C.
    Sebastiani G; Halfon P; Castera L; Mangia A; Di Marco V; Pirisi M; Voiculescu M; Bourliere M; Alberti A
    Aliment Pharmacol Ther; 2012 Jan; 35(1):92-104. PubMed ID: 22035045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease.
    Naveau S; Essoh BM; Ghinoiu M; Marthey L; Njiké-Nakseu M; Balian A; Lachgar M; Prévot S; Perlemuter G
    Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):404-11. PubMed ID: 24561990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrotest-Actitest: the biochemical marker of liver fibrosis--the Israeli experience.
    Morali G; Maor Y; Klar R; Braun M; Ben Ari Z; Bujanover Y; Zuckerman E; Boger S; Halfon P
    Isr Med Assoc J; 2007 Aug; 9(8):588-91. PubMed ID: 17877064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver fibrosis in young Egyptian beta-thalassemia major patients: relation to hepatitis C virus and compliance with chelation.
    Elalfy MS; Esmat G; Matter RM; Abdel Aziz HE; Massoud WA
    Ann Hepatol; 2013; 12(1):54-61. PubMed ID: 23293194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies.
    Bourliere M; Penaranda G; Renou C; Botta-Fridlund D; Tran A; Portal I; Lecomte L; Castellani P; Rosenthal-Allieri MA; Gerolami R; Ouzan D; Deydier R; Degott C; Halfon P
    J Viral Hepat; 2006 Oct; 13(10):659-70. PubMed ID: 16970597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience.
    Grigorescu M; Rusu M; Neculoiu D; Radu C; Serban A; Catanas M; Grigorescu MD
    J Gastrointestin Liver Dis; 2007 Mar; 16(1):31-7. PubMed ID: 17410286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simple biochemical parameters and a novel score correlate with absence of fibrosis in patients with nonalcoholic fatty liver disease.
    Shukla A; Kapileswar S; Gogtay N; Joshi A; Dhore P; Shah C; Abraham P; Bhatia S
    Indian J Gastroenterol; 2015 Jul; 34(4):281-5. PubMed ID: 26341864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.
    Jacqueminet S; Lebray P; Morra R; Munteanu M; Devers L; Messous D; Bernard M; Hartemann-Heurtier A; Imbert-Bismut F; Ratziu V; Grimaldi A; Poynard T
    Clin Gastroenterol Hepatol; 2008 Jul; 6(7):828-31. PubMed ID: 18524692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors.
    Imbert-Bismut F; Messous D; Thibault V; Myers RB; Piton A; Thabut D; Devers L; Hainque B; Mercadier A; Poynard T
    Clin Chem Lab Med; 2004 Mar; 42(3):323-33. PubMed ID: 15080567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.